Overview

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of intramuscular prime-boost regimens of Ad26.RSV.FA2 given either once or twice followed by Ad35.RSV.FA2 (human adenovirus-vectored vaccine candidate) in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Crucell Holland BV